Answer
AdreView (iobenguane) requires careful benefit–risk assessment in patients with renal or hepatic impairment because increased radiation exposure is possible.
Sources for this answer
- AdreView 74 MBq/mL Solution for InjectionGE Healthcare Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 1Document updated
Sources checked